Metadata record for the article: Automated and rapid detection of cancer in suspicious axillary lymph nodes in patients with breast cancer
Creators: name: Li, Juanjuan
name: Downs, Bradley M.
name: Cope, Leslie M.
name: Fackler, Mary Jo
name: Zhang, Xiuyun
name: Song, Chuan-gui
name: VandenBussche, Christopher
name: Zhang, Kejing
name: Han, Yong
name: Liu, Yufei
name: Tulac, Suzana
name: Venkatesan, Neesha
name: Guzman, Timothy de
name: Chen, Chuang
name: Lai, Edwin W.
name: Yuan, Jingping
name: Sukumar, Saraswati
Publisher: name: figshare
Year: 2021
Subjects: Medical and Health Sciences not elsewhere classified
Cancer
Biomarkers

description: <b>Summary</b><br>

This
metadata record provides details of the data supporting the claims of the
related article: “Automated and rapid detection of
cancer in suspicious axillary lymph nodes in patients with breast cancer”.

The
related study proposed that the 5-hour automated GeneXpert system-based
prototype Breast Cancer Detection Assay (BCDA) that quantitatively measures DNA
methylation in ten tumour-specific gene markers could provide a facile,
accurate test for detecting cancer in fine needle aspiration (FNA) of enlarged
lymph nodes.

 

Subject of
data: <i>Homo sapiens</i>

Population
characteristics: women with confirmed breast cancer and enlarged lymph nodes; women
with benign breast disease with enlarged lymph nodes

Recruitment:
For the prospective study, patients were recruited at the outpatient clinic
after confirmation of a diagnosis of breast cancer, prior to sentinel lymph
node biopsy. For the pilot validation study, archival slides were used.

 

<b>Data
access</b>

The following
files contain the raw data associated with BCDA and QM-MSP in Figures 2, 3 and
Supplementary Figures 1, 2, 3, 4, 5, 6, 7 of the related manuscript: ‘Figure2_Data.xlsx’,
‘Figure3_Data.xlsx’ and ‘Sup_Table_Figures.xlsx’.

 

The raw Cts
(cycle threshold at which signal fluorescence exceeds background) of the method
to quantitatively measures DNA methylation are in the file ‘Cepheid_lymphnode_Project.pdf’.

 

None
of the above files are publicly available as they
contain information that could be used to identify patients and informed consent to share participant-level data was not
obtained prior to or during data collection. However, they can be made
available upon request, and data-related requests and enquiries should be
directed to the corresponding author.

 

<b>Corresponding author(s) for this study</b>

Saraswati
Sukumar, Ph. D, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,
1650, Orleans Street, CRB1/144, Baltimore, MD, 21231; Ph: 410-614-2479; Fax:
410-614-4073; saras@jhmi.edu

Jingping
Yuan, M. D., Department of Pathology, Renmin Hospital of Wuhan University, 238,
JieFang Road, WuChang District, Wuhan, Hubei 430060, China PRC; Ph:
8613517288266; 785421101@qq.com<br>
<br>
<b></b>

<b>Study
approval </b>

The
institutional review boards of Renmin Hospital of Wuhan University
(WDRY2018-K062, PI: C. Chen), China, and Johns Hopkins, USA (JH-IRB 00047309,
PI: S Sukumar). The study was conducted in accordance with Declaration of
Helsinki and the U.S. Common Rule. 
Patients provided informed consent for use of excess cells and tissue
for research.

 

<br>